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Objective: Changes in biomarkers for bone and cartilage in knee osteoarthritis (KOA) may reﬂect changes
in tissue turnover induced by interventions. The aim of this study was to assess the effect on osteoar-
thritis biomarkers of an intensive weight loss intervention in obese KOA patients.
Methods: 192 obese KOA patients followed a 16 weeks weight loss intervention (ClinicalTrials.gov:
NCT00655941). Serum Cartilage Oligomeric Matrix Protein (sCOMP), Urine C-terminal telopeptide of
collagen type II (uCTX-II) and type I (uCTX-I) were determined by enzyme-linked immunoassay (ELISA)
at baseline and after 16 weeks. Patient-reported symptoms were assessed by the Knee Injury and
Osteoarthritis Outcome Score (KOOS) Questionnaire without the sports and recreation score (KOOS-4).
Change from baseline was analyzed using Analysis of CoVariance (ANCOVA) adjusting for sex, age, and
body mass index (BMI). Bivariate associations were analyzed using Spearman's test of rank correlation.
Results: 175 patients completed the treatment and lost mean 13.4 (95% CI: 12.5e14.4) kg. sCOMP con-
centration decreased on average 1.1 (95% CI: 1.5 to 0.8) U/L with a correlation to weight loss
(r ¼ 0.17, P ¼ 0.028), but not to change in KOOS-4 (r ¼ 0.13, P ¼ 0.091). uCTX-II increased signiﬁcantly,
mean 69 (95% CI: 31e106) ng/mmol creatinine, with no relation to weight loss (P ¼ 0.14). Change in
uCTX-II was reversely related to change in KOOS-4 (r ¼ 0.28, P ¼ 0.0003). uCTX-I increased, mean 67
(95% CI: 47e87) mg/mmol creatinine, and correlated to weight loss (r ¼ 0.22, P ¼ 0.0007), while not to
KOOS-4 (P ¼ 0.93).
Conclusion: A rapid substantial weight loss in obese KOA patients was weakly, while signiﬁcantly
associated with a reduction in sCOMP, and increases in both uCTX-II and uCTX-I.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.o: E.M. Bartels, The Parker
Hospital, Nordre Fasanvej 57,
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Knee osteoarthritis (KOA) is characterized by loss of articular
cartilage1,2 with changes in thickness, water content and mechan-
ical properties3, as well as changes in the subchondral bone and
osteophyte formation4. Cartilage biomarkers may be used to
describe the degenerative status and prospectively assess meta-
bolic processes of the joint1,5. Among these markers, Cartilage
Oligomeric Matrix Protein (COMP) concentration in blood is a
possible candidate to indicate pathological turnover of cartilage at
early stages of arthritis, preceding ensuing structural breakdown oftd. All rights reserved.
E.M. Bartels et al. / Osteoarthritis and Cartilage 22 (2014) 1817e18251818cartilage visible on radiography6e8, since COMP is suggested to
participate in the forming and maintenance of the cartilage ma-
trix9,10. Another marker is the level of C-terminal telopeptide of
collagen type II in urine (uCTX-II), which has been suggested to be
associated with breakdown of the cartilage type II collagen
network11,12. Bone type I collagen degradationmay, furthermore, be
estimated by the urinary analyses of the C-terminal telopeptide of
collagen type I (uCTX-I)13,14.
A high percentage of KOA patients are overweight or obese, and
weight loss is effective in the symptomatic treatment of KOA15e22.
It remains, however, to be elucidated, whether weight loss also is
beneﬁcial for joint-tissue turnover and thereby may retard devel-
opment of structural damage of the joint in OA.
The aim of the present study was to assess changes in cartilage
and bone biomarker concentration in serum and urine samples
from obese KOA patients exposed to a 16 week weight loss pro-
gram. This program was shown to improve the patient-reported
symptoms18, which raised questions concerning possible disease-
modifying impact of weight loss on markers of cartilage and/or
bone status.
Methods
Study design and setting
The study was approved by the Health Research Ethics com-
mittee of The Capital Region of Denmark [H-B-2007-088] and was
carried out in accordance with the Helsinki Declaration (http://
www.wma.net/en/30publications/10policies/b3/index.html) and
the European Guidelines for Good Clinical Practise (http://www.
efgcp.be/).
Participants
192 KOA patients were recruited from the outpatient clinic at
the Department of Rheumatology, Frederiksberg Hospital,
Denmark, during the period November 2007 to August 2008. The
present report is part of a larger clinical trial, the CAROT study
(‘Inﬂuence of weight loss or exercise on CARtilage in Obese knee
osteoarthriTis patients’, ClinicalTrials.gov identiﬁer:
NCT00655941)18. To be eligible for inclusion, individuals had to be
over 50 years of age, have a body mass index (BMI) 30 kg/m2, and
show primary KOA diagnosed according to the American College of
Rhematology (ACR) criteria23 with clinical symptoms and radio-
graphic veriﬁcation of the diagnosis. All patients gave informed
consent.
Intervention
All participants followed an 8-week formula weight loss diet
415e810 kcal/day, followed by 8 weeks on a hypo-energetic
1200 kcal/day diet with a combination of normal food and for-
mula products as described in detail by Christensen et al.24. This
was supplemented with weekly sessions (1.5 h/week) by a dietician
giving nutritional instructions and behavioral therapy throughout
the 16 weeks. The behavioral therapy was based on current evi-
dence in the ﬁeld of behavior modiﬁcation25 and focused on
modifying the patient's understanding of weight regulation. The
program included formula meal replacements with nutrition
powder and bars (The Cambridge Weight Plan, UK). The initial 8-
week formula weight loss diet met all recommendations for daily
intake of vitamins and minerals. Daily intake of proteinwas at least
43.2 g, essential fatty acids 3 g, and linolenic acid 0.4 g. Dietary ﬁber
intakewasminimum7.2 g a day. Patients were advised to use a ﬁber
supplement to avoid constipation.Measurements
Clinical assessments, as well as variables, were measured prior
to enrollment and following the 16 weeks of dietary intervention.
Collection of fasting blood samples and second morning void urine
samples were performed at the same visit. Samples were taken in
the morning after the patients had transported themselves to the
clinic, and prior to intake of food. This should prevent most of the
diurnal ﬂuctuations26,27 of the biomarkers. Serum samples for
biomarkers were produced from the collected blood samples,
frozen at 20C, and stored at 80C until measurements of all
samples in one batch and at the same time. Urine samples were
frozen directly after collection, and stored at 20C until mea-
surements were carried out on all samples in one batch and at the
same time.
The following clinical indicators for liver function were
measured in plasma at the clinical chemistry department, Freder-
iksberg Hospital (with intra-serial and day-to-day CV%): alanine
aminotransferase (ALT) (1.13 and 2.2), alkaline phosphatase (ALP)
(0.83 and 1.3), total bilirubins (1.7 and 1.9), and amylase (0.79 and
1.3). All were measured with standardized International Federation
of Clinical Chemistry and Laboratory Medicine (IFCC) colorimetric
methods on a Cobas Integra 800 (RocheDiagnostics GmbH, Man-
nheim, Germany). These tests were carried out as a standard to
secure that the subjects in the study do not suffer from liver disease
prior to being exposed to the hypo-caloric diet.Variables
Body weight
Body weight was measured without large clothing and shoes to
the nearest 0.1 kg on a decimal weighing scale (TANITA BW-800,
Frederiksberg Vægtfabrik, Denmark).KOOS
The patients ﬁlled in the Knee Injury and Osteoarthritis
Outcome Score (KOOS)28. Due to the type of patients in the study, it
was chosen to use the scale which was quantiﬁed as the average of
the subscale averages of four of the ﬁve KOOS subscales (Pain;
Symptoms; Function in daily living; and Knee-related quality of
life), here named KOOS-4, with scores ranging from 0 (worst) to 100
(best).Imaging
Standing knee radiographs were assessed using the Altman and
Gold Atlas29, and each of the three knee compartments were
separately scored according to the Kellgren & Lawrence score30.
Details have been published previously by Gudbergsen et al.31Body composition
Lean body mass (LBM, kg), body fat (BF, kg), bone mineral
density (BMD, g/cm2), and bone mineral content (BMC, g) were
determined by dual energy X-ray absorptiometry (DEXA) using a
Lunar DPX IQ Full Body Bone scanner (GE Medical Systems, Madi-
son, WI, USA).C-reactive protein (CRP)
CRPwas determined as amarker for systemic inﬂammation. CRP
was measured in heparin plasma with immuno-turbidimetric ab-
sorption photometry (Roche/Hitachi cobas-C systems, Roche Di-
agnostics GmbH, D-68298Mannheim), with a value10mg/l being
considered normal concentration, detection limit 0.3 mg/l.
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sCOMP was measured in serum with an enzyme-linked
immunoassay (ELISA) (AnaMar, Lund, Sweden) according to the
manufacturer's recommendations. All samples from the same pa-
tient were tested on the same plate. The detection limit was <0.1 U/
L, and the intra-assay and inter-assay coefﬁcient of variation were
less than 5%.
uCTX-II was measured with the use of the Urine CartiLaps® EIA
(Immunodiagnostic Systems Limited (IDS), Boldon, Tyne and Wear
NE35 9PD, UK)11.
uCTX-I was measured with the use of the Urine CrossLaps® EIA
(Immunodiagnostic Systems Limited (IDS), Boldon, Tyne and Wear
NE35 9PD, UK).
The range of CV%s for uCTX-II was from 0 to 27% with 10
samples showing a precision greater than 15%. The median CV%
was 4.1%. The range of CV%s for uCTX-I was from 0 to 18% with
three samples showing a precision greater than 15%. The median
CV% was 4.7%.
The lowest limit of detection is taken as the lowest cali-
brator, which is 130 mg/L for uCTX-I and 0.65 mg/L for uCTX-II.
The number of samples reading below this calibrator was four
and 29 for uCTX-I and uCTX-II, respectively. Where samples
read above the assay range/top calibrator, the samples were
diluted in standard solution as indicated in the kits, and the
concentration corrected back to neat. The number of samples
requiring a dilution was three and 11 for uCTX-I and uCTX-II,
respectively.
The concentrations of uCTX-I and uCTX-II were standardized
to the total urine creatinine at the time of sampling. Urine
creatinine was measured with an enzymatic colorimetric
method (cobas-C systems, Roche Diagnostics GmbH, Mannheim,
Germany). All biomarker measurement fulﬁlled that the
analytical variation did not exceed half of the within-subject
variation.Statistical methods
The overall statistical analysis plan tested the null hypothesis
that none of the biomarker measures included had changed
signiﬁcantly during the intensive weight loss program; i.e., the
dependent variable was the calculated change from baseline. Apart
from compensating for possible effects of gender, we aimed at
compensating potential wide-spread variation of the measured
variables between individuals by examining actual change between
baseline value and value at end of the treatment period.
We used a 1-factor Analysis of CoVariance (ANCOVA) with a
factor for gender, and applied both the level of the outcome at
baseline and age as covariates in the statistical model. A priori we
considered a P-value <0.05 (two-sided) as indicating a rejection of
the null hypothesis. For sensitivity, to support the results from the
group level of the 1-sample t-tests, we also applied Spearman's
correlation analysis to assess whether there was an association
between the weight or symptomatic changes and subsequent
change in biomarker concentrations on the level of the individual
patient.
The ANCOVA model is based on the assumption of independent
residual errors. The model errors are showing a Gaussian (i.e.,
Normal) distribution with homogeneous variance. The model as-
sumptions were investigated graphically by plotting residuals vs
the model predicted values, enabling a visual inspection of outliers
and inﬂuential observations. The SAS statistical package (version
9.2; SAS Institute Inc., Cary, NC, USA) was used for all statistical
analyses.Results
Participant ﬂow and baseline characteristics
192 participants were randomized to the trial, and 175 (91%)
completed the study. Only participants completing the study were
included in the data and further analyses, since our aim was to
determine possible changes in physiological/biochemical pro-
cesses, which may lead to an overall improvement of cartilage
degradation. The dropouts did not differ signiﬁcantly from the
subjects completing the study18.
The baseline characteristics of the cohort are shown in Table I.
The mean age of the participants was 62.6 years (SD 6.3). The
majority of the participants were women (142 [81%] of 175 par-
ticipants). The mean weight at baseline was 102.4 kg (SD 14.5),
corresponding to a BMI of 37.1 kg/m2 (SD 4.4). Kellgren & Lawrence
score was between one and four. At baseline, there was no corre-
lation between Kellgren & Lawrence Score and sCOMP, uCTX-I, and
uCTX-II except that a small population, 5% of the total, being in
either score group three or four showed a higher uCTX-II than seen
in the two lower score groups. The average KOOS-4 at baseline was
54 (SD 14).
CRP values at baseline, with a median of 4.1 mg/l, showed
overall no systemic inﬂammation in the cohort.
ALAT was at baseline in general in the normal range, with only
six patients (3%) being just above the normal range and two (1%),
one man and one woman, qualifying for the clinically deﬁned light
increase of 2e5 times the maximumvalue of the reference interval.
ALAT was not correlated to sCOMP. ALP was in the normal range.
Amylase was in the normal range, except in four individuals with a
slightly lower concentration, and bilirubins were found to be in the
normal range with only four being just below the cut-off range.
General treatment response
The 175 participants who completed the 16 weeks weight loss
scheme showed a signiﬁcant weight loss with a mean of 13.4 kg
(95% CI: 12.5e14.4). KOOS-4 also showed a signiﬁcant improve-
ment of 10 (95% CI: 7.7e12.3). A summary of measured changes
following weight loss is shown in Table II.
Following weight loss, an average signiﬁcant drop in CRP level of
1.3 mg/l was seen in this cohort. ALAT did decrease signiﬁcantly
following weight loss, and only four (2%) showed a small increase
above normal range, while not clinically signiﬁcant. ALP did not
change with the weight change. Amylase was also found to be in
the normal range. Bilirubins were following the weight loss in the
normal range for all participants.
Biomarkers of cartilage and bone
Baseline values are given in Table I, and changes from baseline to
16 weeks in Table II. No differences were found between males and
females. At baseline the uCTX-II and uCTX-I was statistically asso-
ciated (Spearman, rho ¼ 0.54; P < 0.0001), while COMP was not
associatedwith uCTX-II (Spearman, rho¼ 0.13; P¼ 0.078) or uCTX-I
(Spearman, rho ¼ 0.018; P ¼ 0.81).
sCOMP
Following weight loss, sCOMP decreased statistically signiﬁ-
cantly with a mean decrease of 1.1 U/l (95% CI: 1.5 to 0.8,
P < 0.0001), and the decrease in sCOMP was found to be correlated
to weight loss (r ¼ 0.17; P ¼ 0.028) [Fig. 1 (A)]. Furthermore, we
also explored the associations of the change in sCOMP with the
change in body weight (P ¼ 0.023) with simultaneous adjustment
for the sCOMP level at baseline (P¼ 0.0001), sex (P¼ 0.79), and age
Table I
Baseline characteristics of the KOA patients prior to diet treatment
Variable Total Min Max Female patients Male patients
N Mean SD N Mean SD N Mean SD
Age, years 175 62.6 6.3 49.6 76.5 142 62.6 6.3 33 62.4 6.4
Height, cm 175 166.2 8.1 148.0 191.0 142 163.8 6.2 33 176.8 6.7
Weight, kg 175 102.4 14.5 76.0 145.0 142 99.8 13.2 33 113.8 14.8
BMI*, kg/m2 175 37.1 4.4 30.1 51.6 142 37.2 4.5 33 36.3 4.0
Fat mass, kg 175 46.6 9.2 30.7 80.7 142 47.8 8.9 33 41.5 8.9
LBMyy, kg 175 50.6 8.7 37.1 78.4 142 47.2 4.6 33 65.2 6.5
BMCy, g 175 2781 463 1931 4134 142 2640 329 33 3384 473
BMDz, g/cm2 175 1.20 0.09 0.94 1.46 142 1.18 0.08 33 1.27 0.11
KLx worst 174 2.6 0.9 1.0 4.0 141 2.6 0.9 33 2.8 0.9
kKOOS_A 175 60.4 16.8 11.8 98.5 142 61.5 16.9 33 55.8 15.7
kKOOS_P 175 57.4 16.0 11.1 100.0 142 57.6 16.4 33 56.7 14.9
kKOOS_Q 175 38.3 16.2 0.0 81.3 142 39.3 15.7 33 33.7 17.6
kKOOS_S 175 60.9 16.9 14.3 96.4 142 59.9 16.8 33 64.9 16.9
KOOS-4 175 54.2 14.4 12.6 89.7 142 54.6 14.5 33 52.8 14.3
Variable Total Min Max Female patients Male patients
N Median Q1 Q3 N Median Q1 Q3 N Median Q1 Q3
CRP, mg/l 175 4.1 2.1 7.6 0.4 58.6 142 4.0 2.3 6.8 33 4.6 1.4 8.9
sCOMP, U/l 175 11.6 9.6 13.5 5.8 19.8 142 11.5 9.5 13.5 33 12.0 9.9 13.4
uCTX-I, mg/mmol creatinine 172 161 104 226 14 553 139 170 116 233 33 113 62 170
uCTX-II, ng/mmol creatinine 172 437 278 663 81 1614 139 472 285 682 33 322 251 411
¶ALAT, U/l 174 26 21 35 6 197 141 26 20 34 33 30 25 44
#ALP, U/l 175 72 62 83 38 148 142 73 63 84 33 65 56 77
**Bilirubines, mM/l 175 7 6 9 2 20 142 7 6 9 33 8 7 11
**Amylase, U/l 175 44 36 57 12 117 142 44 35 56 33 46 36 62
* Body Mass Index.
y Bone Mineral Content.
z Bone Mineral Density.
x Kellgren & Lawrence score.
k KOOS subscales are: A¼ Function in daily living; P¼ Pain; Q¼ knee-related Quality of life; S¼ Symptoms; SP¼ Function in Sport and recreation; KOOS-4 is the joint KOOS
for KOOS-A, -P, -Q and -S.
¶ Plasma alanine aminotransferase.
# Plasma alkaline phosphatase.
** Measured in plasma.
yy Lean Body Mass.
Table II
Change of variables from baseline with crude estimates and measures of dispersion and adjusted estimates with 95% conﬁdence intervals to week 16, in KOA patients exposed
to diet treatment
Variable Change from baseline (crude) Min Max Change from baseline (adjusted model)*
N Mean SD Median LSMean (95% CI) P-value
DWeight, kg 175 14.0 4.8 13.9 28.9 1.0 13.4 (14.4; 12.5) <0.0001
DFM, kgy 175 11.0 3.9 11.1 2.2 13.7 11.2 (11.9; 10.4) <0.0001
DLBM, kgz 175 1.8 3.1 1.8 6.9 28.1 0.7 (1.5; 0.1) 0.089
DBMC, gx 175 13.5 132.6 31 481 850 0.2 (27.9; 27.5) 0.99
DBMD, g/cm2k 175 0.004 0.024 0.000 0.058 0.087 0.010 (0.006; 0.015) <0.0001
DKOOS_Ayy 175 12.1 14.1 11.8 47.1 51.5 12.5 (10.0; 15.1) <0.0001
DKOOS_Pyy 175 10.7 14.5 11.1 33.3 58.3 10.0 (7.3; 12.7) <0.0001
DKOOS_Qyy 175 9.4 16.4 12.5 37.5 56.3 8.1 (5.1; 11.1) <0.0001
DKOOS_Syy 175 9.9 13.5 10.7 28.6 46.4 8.7 (6.1; 11.3) <0.0001
DKOOS_4 175 10.5 12.1 10.2 22.8 51.3 10.0 (7.7; 12.3) <0.0001
DCRP, mg/l 175 1.3 5.7 0.7 38.6 18.6 1.3 (2.1; 0.01) 0.0021
DsCOMP, U/l 175 1.2 2.0 1.3 5 6.7 1.1 (1.5; 0.8) <0.0001
DuCTX-I, mg/mmol creatine 169 77 102 70 368 446 67 (47; 87) <0.0001
DuCTX-II, ng/mmol creatine 169 55 199 59 653 700 69 (31; 106) 0.0005
¶DALAT, U/l 174 5.0 20.2 3.0 151.0 55.0 4.8 (7.2; 2.5) <0.0001
#DALP, U/l 175 1.0 13.2 3.0 24.0 68.0 1.8 (4.3; 0.7) 0.16
**DBilirubines, mM/l 175 0.6 3.0 1 9 10 0.4 (0.1; 1.0) 1.0
DAmylase, U/l 175 4.5 8.5 4 21 33 4.5 2.8 6.1
* Analyzed using ANCOVA using the baseline variable, baseline BMI, and age as covariates; sex was applied as a factor.
y Fat Mass.
z Lean Body Mass.
x Bone Mineral Content.
k Bone Mineral Density.
¶ Plasma alanine aminotransferase.
# Plasma alkaline phosphatase.
** Measured in plasma.
yy KOOS subscales are: A¼Function in daily living; P¼Pain; Q¼knee-related Quality of life; S¼Symptoms; SP¼Function in Sport and recreation;KOOS-4 is the joint KOOS for
KOOS-A, -P, -Q and -S.
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Fig. 1. Changes in the three biomarkers sCOMP (A), uCTX-II (B), and uCTX-I (C) as a function of weight change over 16 weeks in 175 KOA patients exposed to a 16-week diet
treatment.
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Appendix 1.
The correlation between change in sCOMP and KOOS-4 after
weight loss did not reach statistical signiﬁcance (r ¼ 0.13;
P ¼ 0.09) [Fig. 2 (A)].uCTX-II
At baseline there was a wide range of the uCTX-II concentration
between individuals, Table I. Following weight loss, uCTX-II
increased signiﬁcantly with a mean increase of 69 ng/mmol
creatinine (95% CI: 31e106, P ¼ 0.0005), Table II, but with no sta-
tistically signiﬁcant correlation between the degree of weight loss
and change in uCTX-II (r ¼ 0.11, P ¼ 0.14), Fig. 1(B). There was no
direct correlation between weight loss and change in uCTX-II
following weight loss, Fig. 1(B).
The change in uCTX-II showed the following associations with
the change in body weight (P ¼ 0.48) with simultaneous adjust-
ment for the uCTX-II level at baseline (P ¼ 0.0001), sex (P ¼ 0.96),
and age (P ¼ 0.76), as well as the body weight at baseline
(P ¼ 0.062); see Appendix 1.
Changes in uCTX-II showed a negative association with changes
in KOOS-4 (r ¼ 0.27; P ¼ 0.0003), indicating improvement of the
patient's experience of their knee-related problemswith a decrease
in uCTX-II, Fig. 2(B).uCTX-I
uCTX-I showed a wide range of individual values at baseline,
Table I. Following weight loss, uCTX-I increased signiﬁcantly with a
mean increase of 67 mg/mmol creatinine (95% CI: 47e87,
P¼ 0.0001), Table II. Change in uCTX-I was correlated toweight loss
(P ¼ 0.005), showing an increase in uCTX-I with increasing weight
loss, Fig. 1(C).
The change in uCTX-I was associated with the change in body
weight (P ¼ 0.0012) with simultaneous adjustment for the uCTX-I
level at baseline (P ¼ 0.0013), sex (P ¼ 0.13), and age (P ¼ 0.33),
as well as the body weight at baseline (P ¼ 0.59); see Appendix 1.
Change in uCTX-I was not associated with change in KOOS-4
(r ¼ 0.006; P ¼ 0.93), Fig. 2(C).Discussion
sCOMP
sCOMP in our cohort was at baseline in the range earlier
observed for KOA patients32. Following weight loss, a group-wise
reduction was seen, but with considerable in-group variation.
The beneﬁt of weight loss in obese KOA patients is traditionally
thought to work through a decrease of the mechanical loading of
the weight-bearing joints. Our results are in accordance with the
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Fig. 2. Changes in sCOMP (A), uCTX-II (B), and uCTX-I (C) as a function of symptomatic change measured by KOOS-4 in 175 KOA patients following a 16-week diet treatment.
E.M. Bartels et al. / Osteoarthritis and Cartilage 22 (2014) 1817e18251822notion of an up-regulated COMP production in osteoarthritis
related to the mechanical loading of a joint33,34. This production
would be expected to be down-regulated following the weight loss.
Our patients were at study start heavily obesewith possible liver
steatosis and ﬁbrosis, and sCOMP is known to be raised in diseases
with ﬁbrosis35,36. It may therefore be speculated if the rapid and
substantial weight loss itself could cause a change in metabolism
affecting sCOMP due to improvement of the liver function. Looking
at our group of patients, their liver condition was, however, not
affected to an extent that was detectable by changes in ALAT. There
was neither correlation between sCOMP and ALAT at baseline, nor
between change in ALAT and change in sCOMP over time.
In contrast to the relatively small changes in sCOMP in our
material, a 36% drop in sCOMP has been reported following a 20%
weight loss in obese KOA patients studied prior to and 6 months
after gastric surgery, mainly Roux-en-Y37. Presence of liver steatosis
and ﬁbrosis would also have been more likely in these morbidly
obese individuals than in our cohort. Furthermore, a stomach
bypass is certain to induce physiological changes in other tissues
than knee cartilage and affect digestion and metabolism beyond
any diet scheme38.
Yet another explanation for our observed decrease in sCOMP
could be that the decrease represented a decrease in synovitis in
the knee joints of our patient group, since decrease in synovitis has
been shown to lead to a decrease in sCOMP39. Our MR synovitis
scores showed in general no change in synovitis following the timeof 16 weeks weight loss intervention40. Another consideration is
that sCOMP may originate from other tissues than the joint carti-
lage, and such tissues, e.g., skin, may also be affected by the dieting
and weight loss37. A positive correlation between sCOMP and BMI
has been shown in OA patients41, and an earlier study showed a
weak correlation between sCOMP and weight loss in OA patients42.
The observed decrease in sCOMP in our study may therefore simply
be due to change in the metabolic processes during weight loss.
Finally, the change in sCOMP following weight loss was not
signiﬁcantly associated with self-assessed symptomatic changes in
the present study which again cannot support the origin of the
sCOMP changes in our study. One must though keep in mind that
self-reported symptoms and joint damage in OA are not very well
related43,44.
uCTX-I and -II
In accordance with an earlier study of KOA45, uCTX-II was on
average 30% higher in our patients than in a healthy population46.
To our surprise, uCTX-II increased following the weight loss (at
week 16), while not related to amount of weight loss. The negative
association between uCTX-II and KOOS-4 did though indicate that a
lower uCTX-II could be related to a healthier knee condition.
An increase in uCTX-II over time has been suggested to repre-
sent an increase in cartilage degradation11,47, but recent studies by
van Spiel et al. suggest that uCTX-II is more strongly related to the
E.M. Bartels et al. / Osteoarthritis and Cartilage 22 (2014) 1817e1825 1823bone biomarkers than to the cartilage ones48. At present uCTX-II is a
dubious marker for a change in cartilage metabolism49 and our
ﬁndings of an increase in uCTX-I level with the weight loss may
indicate that the increase in both of these markers was due to up-
regulated bone turnover with the weight loss50,51. In our material,
BMC did not change signiﬁcantly during the 16 weeks of weight
loss, and BMD showed only a slight increase (less than 1%)25. This
ﬁnding was suggested to be caused by securing that the diet
included all essential nutrients25.Study limitations
The rather dramatic change in diet during this period may by
itself have inﬂuenced any biomarker. To reduce this effect to some
extent, all samples were taken fasting and at the same time in the
morning. Although most of the participants were rather sedentary,
the weight loss may have increased their physical activity. This
would have increased the COMP concentration52, and opposite
changes after weight loss in s-COMP may thus have been leveled
out by such effect. Unfortunately we do not have accurate re-
cordings of the patients' physical activity level prior to and
following the treatment. Finally, the large variations in grade of
knee OA in our material must be noted. Although 81% of the par-
ticipants had a KL-score between 1 and 34,31, this will still represent
a varied picture concerning cartilage. The KL-grading is a useful, but
in terms of biochemically active tissue, a crude measure of active
cartilage. Some participants with higher Kellgren& Lawrence grade
may therefore not have had the potential in terms of cell content to
create a change during the time of intervention.
The patient-reported outcomes differ widely with cartilage
status, which in general inhibits interpretations of possible re-
lationships between biomarkers and symptoms43,44.Conclusion
A substantial weight loss over 16 weeks in obese KOA patients
caused a slight reduction in S-COMP concentration, which was
associated with the magnitude of weight loss. Both uCTX-II and
uCTX-I were found to increase, and while not correlated to the
weight lost, the changes might reﬂect a bone remodeling following
weight loss. The discrepant results with different biomarkers
markers preclude ﬁrm conclusions.Source DF Type III SS Mean square F value P-value
Dependent variable
Change
in COMP:
Comp_0 1 56.079 56.079 15.77 0.0001
Female 1 0.254 0.254 0.07 0.7895
Age 1 2.490 2.490 0.7 0.4038
Weight_0 1 0.364 0.364 0.1 0.7494
dWeight 1 18.643 18.643 5.24 0.0233
Change
in CTX1:
CTX1crea_0 1 100669.583 100669.583 10.64 0.0013
Female 1 22,453.030 22,453.030 2.37 0.1254
Age 1 9021.130 9021.130 0.95 0.3303
Weight_0 1 2767.220 2767.220 0.29 0.5894
dWeight 1 103270.729 103270.729 10.91 0.0012
Change
in CTX2:
CTX2crea_0 1 0.548 0.548 15.27 0.0001
Female 1 0.000 0.000 0 0.9598
Age 1 0.003 0.003 0.09 0.7622
Weight_0 1 0.127 0.127 3.53 0.0621
dWeight 1 0.018 0.018 0.49 0.4839Author contributions
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